Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

749
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
749
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sex-biased Genetic Risk Loci and Causal Brain Proteins in Parkinson's Disease.

medRxiv : the preprint server for health sciences·2026
Same author

Differential DNA methylation in blood as potential mediator of the association between ambient PM<sub>2.5</sub> and cerebrospinal fluid biomarkers of Alzheimer's disease among a cognitively normal population-based cohort.

Molecular psychiatry·2026
Same author

Uncovering lipid biomarkers linked to methylphenidate efficacy in treating apathy in Alzheimer's disease: insights from the ADMET 2 trial.

Alzheimer's research & therapy·2026
Same author

DEVELOPMENT AND APPLICATION OF BRAIN TISSUE BASED MULTI-OMICS PROFILE SCORES FOR ALZHEIMER'S DISEASE.

Research square·2026
Same author

Genetic and Proteomic Investigation of the Smoking-Parkinson's Disease Association.

medRxiv : the preprint server for health sciences·2026
Same author

Behavioral and psychological symptoms of dementia: insights from a multivariate and network-based brain proteome-wide study.

medRxiv : the preprint server for health sciences·2026

Related Experiment Video

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

Biomarkers.

Donghai Liang1, Youran Tan1, Emma Casey1

  • 1Emory University, Atlanta, GA, USA.

Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|December 26, 2025
PubMed
Summary
This summary is machine-generated.

Alzheimer's disease (AD) brain metabolomics revealed 155 metabolic features and 36 pathways linked to neuropathology. Genetic factors, like APOE ε4, influence these metabolic changes in AD.

More Related Videos

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

Related Experiment Videos

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

Area of Science:

  • Neuroscience
  • Metabolomics
  • Genetics

Background:

  • Alzheimer's disease (AD) is a neurodegenerative disorder with poorly understood links between metabolism and neuropathology.
  • Metabolomics offers a way to identify metabolic signatures and pathways involved in AD progression.

Purpose of the Study:

  • To investigate metabolic perturbations in the brain associated with AD neuropathology using high-resolution metabolomics.
  • To identify specific metabolic pathways and metabolites implicated in AD progression.
  • To explore the influence of APOE ε4 genotype on AD-associated metabolic changes.

Main Methods:

  • Analyzed 162 frontal cortex samples using untargeted high-resolution metabolomics.
  • Performed metabolome-wide association studies correlating metabolic features with neuropathological markers (Braak stage, CERAD, ABC scores).
  • Conducted pathway enrichment analysis and confirmed key metabolites with Level 1 evidence, assessing APOE ε4 effects.

Main Results:

  • Identified 155 metabolic features and 36 pathways associated with AD neuropathology markers across ten metabolic classes.
  • Found distinct metabolic associations for Braak stage (nucleotide metabolism) and CERAD (fatty acid metabolism).
  • Confirmed 18 metabolites involved in amino acid, lipid, carbohydrate, and nucleotide metabolism; APOE ε4 non-carriers showed stronger perturbations in specific metabolites.

Conclusions:

  • High-resolution brain metabolomics can elucidate molecular mechanisms of AD pathology.
  • Findings provide insights into metabolic dysregulation in AD and its interaction with genetic factors.
  • Further longitudinal studies are needed to validate findings and explore the functional significance of identified metabolites.